Ligand id: 6884

Name: eculizumab

1. Evans MJ, Matis L, Mueller EE, Nye SH, Rollins S, Rother RP, Springhorn JP, Squinto SP, Thomas TC, Wang Y et al.. (1995)
Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases.
Patent number: WO1995029697A1. Assignee: Alexion Pharma Inc.. Priority date: 02/05/1994. Publication date: 09/11/1995.
2. Horiuchi T, Tsukamoto H. (2016)
Complement-targeted therapy: development of C5- and C5a-targeted inhibition.
Inflamm Regen, 36: 11. [PMID:29259684]
3. Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan S et al.. (2019)
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
N. Engl. J. Med., 381 (7): 614-625. [PMID:31050279]
4. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. (2007)
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
Nat. Biotechnol., 25 (11): 1256-64. [PMID:17989688]
5. Sheridan D, Yu ZX, Zhang Y, Patel R, Sun F, Lasaro MA, Bouchard K, Andrien B, Marozsan A, Wang Y et al.. (2018)
Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action.
PLoS ONE, 13 (4): e0195909. [PMID:29649283]